ProKidney Corp. - Class A Ordinary Shares - Nakit Akışı (NASDAQ:PROK) | MetaTrader

Tam grafiği aç Full chart

Financials

Genel Bakış Tablolar İstatistikler

Çeyreklik Yıllık

İşletme faaliyetlerinden elde edilen nakit —-77.09 M-90.07 M-126.35 M-120.12 M -132.21 M Yatırım faaliyetlerinden elde edilen nakit —-1.74 M-329.98 M20.41 M103.97 M 110.5 M Finansman faaliyetlerinden elde edilen nakit —548.52 M-9.55 M144.41 M25.57 M 25.8 M Serbest nakit akışı —-77.09 M-90.07 M-126.35 M-135.31 M -150.06 M

Haberler

ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates

ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Beats Revenue Estimates

ProKidney ticari başkan olarak Greg Madison’ı atadı

BofA, ProKidney hissesi için Düşük Performans notunu korudu

Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue Estimates

Aquestive Therapeutics (AQST) Reports Q4 Loss, Misses Revenue Estimates

ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably (NASDAQ:PROK)

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:PROK) 2026-01-14

H.C. Wainwright, ProKidney hissesi için Al tavsiyesi ve 12 dolar hedef fiyat belirledi

H.C. Wainwright initiates ProKidney stock with Buy rating, $12 target